Competitive Landscape in the Global Multiple Myeloma Market and Sarclisa's Position

Sanofi's CD38-directed cytolytic antibody therapy, Sarclisa (generic name: isatuximab-irfc), is expanding its footprint in the global multiple myeloma market. The global multiple myeloma treatment market, valued at approximately $28 billion in 2024, is growing rapidly due to aging populations and the adoption of high-cost targeted therapies. Sarclisa generated €588 million (approximately $700 million) in global sales in 2025, representing a 28.5% year-over-year increase. However, it still lags significantly behind Johnson & Johnson's Darzalex, which reported $14.35 billion in sales. To expand its market share, Sanofi is strategically pursuing broader combination therapy approvals and launching more convenient formulations, securing regulatory approvals step by step.

Sarclisa's FDA Approval Journey and Clinical Value of Combination Therapies

Sarclisa's FDA product license approval (BLA 761113) reflects a phased approach, starting from a later-line therapy to entering the first-line treatment market. It was initially approved in March 2020 for patients with relapsed/refractory multiple myeloma (RRMM) who had received at least two prior therapies, in combination with pomalidomide and dexamethasone (Isa-Pd). In March 2021, its indication was expanded to include combination with carfilzomib and dexamethasone (Isa-Kd). In September 2024, it received approval for newly diagnosed multiple myeloma (NDMM) patients who are ineligible for autologous stem cell transplantation (ASCT), in combination with bortezomib, lenalidomide, and dexamethasone (Isa-VRd). This expansion into the first-line treatment market is a key part of Sanofi's mid-to-long-term strategy to diversify its business and secure real growth momentum.

Enhancing Patient Convenience and Market Competitiveness through Subcutaneous (SC) Formulation

The most important short-term milestone for Sarclisa is the FDA approval of its subcutaneous (SC) formulation using an on-body injector. While the intravenous (IV) formulation requires patients to remain in the hospital for several hours, the SC formulation significantly reduces infusion time, thereby improving patient quality of life and hospital efficiency. Given that Johnson & Johnson has already strengthened its market leadership with the subcutaneous formulation of Darzalex Faspro, Sanofi is under urgent pressure to secure this formulation approval to defend and expand its market share. The FDA has extended the review deadline (PDUFA Target Action Date) to July 23, 2026, due to requests for additional data on the delivery device. The industry expects this approval to serve as a critical stepping stone for market penetration.

Importance of Clinical Safety Profile and Regulatory Compliance

However, rapid adoption by clinicians will depend on proper management of adverse events as outlined in the product label and adherence to regulatory guidelines. Sarclisa carries warnings for infusion-related reactions, severe neutropenia, and an increased risk of secondary primary malignancies, requiring careful monitoring by healthcare providers. Additionally, the drug may interfere with blood typing and serological testing before transfusion, potentially causing confusion in test result interpretation. Sanofi is reinforcing its safety management system based on the strong clinical efficacy and progression-free survival (PFS) data demonstrated in the IMROZ Phase 3 trial, aiming to solidify trust among clinicians and regulatory authorities.